» Articles » PMID: 30063647

Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda

Overview
Date 2018 Aug 1
PMID 30063647
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Throughout the world, there are antiretroviral therapy-naive HIV+ individuals who maintain elevated peripheral CD4 T-cell counts, historically referred to as long-term nonprogressors (LTNPs). With recent improvements in viral load (VL) detection methods to levels as low as 20 copies per milliliter, 2 subsets of LTNPs have been defined: elite controllers (ECs), with undetectable VLs for at least 6-12 months, and viremic controllers (VCs), with VLs between 200 and 2000 copies per milliliter. ECs and VCs have been extensively studied in the developed world to determine underlying mechanisms responsible for virologic control. In sub-Saharan Africa, most studies have characterized LTNPs based on immunologic criteria making it difficult to compare findings with the Western cohorts, which use virologic criteria. Here, we describe a cohort of Uganda ECs and VCs attending a large HIV ambulatory center in Kampala, Uganda, based initially on CD4 counts and confirmed by repeated VL measurements.

Methods: A cross-sectional study was conducted among 14,492 HIV-infected, antiretroviral therapy-naive individuals aged 18 years and older under care for at least 5 years with serial peripheral CD4 counts ≥500 cells/μL. Among those, we determined the frequency of individuals with VLs <2000 copies per milliliter for at least 6 months.

Results: We report a prevalence of 0.26% (38/14,492) of HIV controllers in the clinic. We identified 36 ECs and 2 VCs. These individuals were middle-aged with an average CD4 count of 858 ± 172 (mean ± SD, 95% confidence interval: 795 to 921). Their average duration in HIV care was 7.4 ± 2.1 years (mean ± SD, 95% confidence interval: 6.6 to 8.1). The majority of EC/VCs were women (87%, 33/38), reflecting the demographics of the urban clinic.

Conclusions: For the first time, this study demonstrates the frequency of EC/VCs in a large urban clinic in Uganda. Further study of these East African subjects may provide insights into how some individuals are able to control HIV in the absence of medications.

Citing Articles

Comparison of the Biological Basis for Non-HIV Transmission to HIV-Exposed Seronegative Individuals, Disease Non-Progression in HIV Long-Term Non-Progressors and Elite Controllers.

Hokello J, Tyagi P, Dimri S, Sharma A, Tyagi M Viruses. 2023; 15(6).

PMID: 37376660 PMC: 10301403. DOI: 10.3390/v15061362.


Reduced CCR5 expression among Uganda HIV controllers.

Nyiro B, Amanya S, Bayiyana A, Wasswa F, Nabulime E, Kayongo A Retrovirology. 2023; 20(1):8.

PMID: 37231494 PMC: 10210444. DOI: 10.1186/s12977-023-00626-7.


Prevalence of undetectable and suppressed viral load in HIV-infected pregnant women initiating Option B+ in Uganda: an observational study nested within a randomized controlled trial.

Gabagaya G, Rukundo G, Amone A, Wavamunno P, Namale-Matovu J, Lubega I BMC Infect Dis. 2021; 21(1):907.

PMID: 34481464 PMC: 8417996. DOI: 10.1186/s12879-021-06608-4.


Immunogenetic determinants of heterosexual HIV-1 transmission: key findings and lessons from two distinct African cohorts.

Tang J Genes Immun. 2021; 22(2):65-74.

PMID: 33934119 PMC: 8225584. DOI: 10.1038/s41435-021-00130-y.


A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo.

Berg M, Olivo A, Harris B, Rodgers M, James L, Mampunza S EBioMedicine. 2021; 65:103258.

PMID: 33674212 PMC: 7992073. DOI: 10.1016/j.ebiom.2021.103258.


References
1.
Laeyendecker O, Redd A, Lutalo T, H Gray R, Wawer M, Ssempijja V . Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda. J Acquir Immune Defic Syndr. 2009; 52(3):316-9. PMC: 2837462. DOI: 10.1097/QAI.0b013e3181bc08f5. View

2.
Okulicz J, Marconi V, Landrum M, Wegner S, Weintrob A, Ganesan A . Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009; 200(11):1714-23. DOI: 10.1086/646609. View

3.
Deeks S, Walker B . Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007; 27(3):406-16. DOI: 10.1016/j.immuni.2007.08.010. View

4.
Morgan D, Mahe C, Mayanja B, Okongo J, Lubega R, Whitworth J . HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS. 2002; 16(4):597-603. DOI: 10.1097/00002030-200203080-00011. View

5.
Walker W, Kurscheid S, Joshi S, Lopez C, Goh G, Choi M . Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. J Virol. 2015; 89(10):5502-14. PMC: 4442529. DOI: 10.1128/JVI.00118-15. View